Sulfonylureas (SUs) have been used for the treatment of hyperglycemia for more than 60
years and are currently the second most commonly prescribed antidiabetic agents …

Background Diabetes, a chronic disease worldwide, may be associated with a poorer
prognosis in patients with coronavirus disease 2019 (COVID-19). While some …

Dear Editor, In their anecdotal report, Bossi and colleagues demonstrate that ''off-label''use
of sodium–glucose cotransporter2 (SGLT2) inhibitors in three subjects with severe or critical …

Objective: To explore mechanistic benefits of glucose-lowering agents that extend beyond
glycemic control with the potential to mitigate coronavirus disease 2019 (COVID-19) …

However, there is a strong counter-argument to this; a number of preclinical studies have
highlighted the potential of SGLT2i to ameliorate systemic and tissue-specific inflammation …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering
agents which have changed the landscape of diabetes therapy, due to their remarkable …

Sir, The observations provided in the letter ''Sodium–glucose cotransporter 2 inhibitors
[SGLT2-i] and major COVID-19 outcomes: promising mechanisms, conflicting data, and …

Novel coronavirus infectious disease (COVID-19) has been recognised as a pandemic by
the World Health Organization (WHO) 1. Mortality and morbidity are higher in elderly …

There is a scarcity of information on the population with diabetes mellitus type 2 and
cardiomyopathy (PDMC) in COVID-19, especially on the association between anti-diabetic …

Abstract Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are widely prescribed in
people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is …